SNPHY Santen Pharmaceutical Company (PK)

By Matt Grossman

Aerie Pharmaceuticals Inc. has completed patient enrollment of a Phase 3 study in Japan testing its netarsudil ophthalmic solution as a treatment for glaucoma or ocular hypertension, Aerie said Thursday.

The Durham, N.C.-based pharmaceutical company said that the study has enrolled 245 patients. The patients have received treatment either with netarsudil or with ripasudil, another solution that is approved in Japan. The trial is expected to be completed by the end of 2021, Aerie said.

Netarsudil has already been approved to treat some eye conditions in the U.S. The Japanese study is being co-funded with Santen Pharmaceutical Co., which has an exclusive collaboration and license agreement with Aerie for netarsudil in Japan and other Asian countries.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

June 17, 2021 06:55 ET (10:55 GMT)

Grafico Azioni Santen Pharmaceutical (PK) (USOTC:SNPHY)
Storico
Da Feb 2025 a Mar 2025

Grafico Azioni Santen Pharmaceutical (PK) (USOTC:SNPHY)
Storico
Da Mar 2024 a Mar 2025